PF-Atlas › Clinical Trials › NCT05022771

A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015

PMG1015 Dose 1 · Phase 1

Registry ID
NCT05022771
Phase
Phase 1
Status
Completed
Drug / intervention
PMG1015 Dose 1
Sponsor
Pulmongene Ltd.
Start
2021-10-14
Enrollment
54
Locations
1

About this trial

This is a Phase 1A, first in human, randomized, double-blinded, placebo-controlled, dose escalation study of PMG1015 in healthy adult volunteers. PMG1015 is a monoclonal antibody, being developed as a novel therapeutic treatment for patients with Idiopathic Pulmonary fibrosis (IPF). This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PMG1015 after Single ascending doses (SAD).

View NCT05022771 on ClinicalTrials.gov →

Explore related

All PMG1015 Dose 1 trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT05022771 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.